Codi QR

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC

Introduction: Ramucirumab (RAM) plus erlotinib was found to have superior progression-free survival (PFS) versus placebo plus erlotinib in untreated EGFR-mutated metastatic NSCLC in the global phase 3 RELAY study. RELAY+ was an open-label, two-period, single-arm, exploratory study of RAM plus gefiti...

Descripció completa

Guardat en:
Autors principals: Makoto Nishio, MD, PhD, Kazuto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Fumio Imamura, MD, PhD, Tomoya Kawaguchi, PhD, Hiroyuki Yamaguchi, MD, PhD, Satoshi Ikeda, MD, PhD, Katsuya Hirano, MD, Carla Visseren-Grul, MD, Matteo Ceccarelli, PharmD, MS, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Tomoko Matsui, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2022-04-01
Col·lecció:JTO Clinical and Research Reports
Matèries:
East Asia
Japan
Plasma biopsy
Treatment outcome
Vascular endothelial growth factor receptor-2
Accés en línia:http://www.sciencedirect.com/science/article/pii/S2666364322000273
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars